Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

View all journals
Search
Log in

nature
search

Search

Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Nature Medicine (2)
Nature Cancer (2)
Nature Communications (1)
Scientific Reports (1)
Nature Cardiovascular Research (1)

Choose more journals

Article type Check one or more article types to show results from those article types only.

Research (5)
Amendments and Corrections (2)

Subject Check one or more subjects to show results from those subjects only.

Cancer
Cardiology
Evolution
Genetics
Immunology
Oncology
Stem cells

Date Choose a date option to show results from those dates only.

Today
Last 7 days
Last 30 days
Last 12 months
Last 2 years
Last 5 years

Custom date range

Clear all filters

Sort by:

Relevance

Date published (new to old)

Date published (old to new)

Showing 1–7 of 7 results

Advanced filters: Author: Fabio M. Iwamoto Clear advanced filters

ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma

In two cohorts of patients with glioblastoma who received anti-PD-1, Sonabend and colleagues show that ERK1/2 phosphorylation, detected by immunohistochemistry, provides a biomarker for MAPK/ERK pathway activity and better survival on this therapy.

Víctor A. Arrieta
Andrew X. Chen
Adam M. Sonabend
Research29 Nov 2021
Nature Cancer

Volume: 2, P: 1372-1386
A real-world observation of patients with glioblastoma treated with a personalized peptide vaccine

Despite new treatment options, prognosis for patients with glioblastoma (GBM) remains poor. Here the authors report the clinical course of patients with GBM treated with a personalized neoantigen-derived peptide vaccine treated within the scope of an individual healing attempt.

Pauline Latzer
Henning Zelba
Saskia Biskup
ResearchOpen Access11 Aug 2024
Nature Communications

Volume: 15, P: 1-9
Author Correction: Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma

Junfei Zhao
Andrew X. Chen
Raul Rabadan
Amendments and Corrections17 Apr 2019
Nature Medicine

Volume: 25, P: 1022
Publisher Correction: ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma

Víctor A. Arrieta
Andrew X. Chen
Adam M. Sonabend
Amendments and Corrections11 Feb 2022
Nature Cancer

Volume: 3, P: 373
Bone marrow adipocytes fuel emergency hematopoiesis after myocardial infarction

Zhang et al. show that bone marrow fatty acid metabolism fuels expanded leukocyte production after myocardial infarction and, based on mouse, pig and human data, suggest that lipolysis in marrow adipocytes provides fatty acids to hematopoietic stem cells.

Shuang Zhang
Alexandre Paccalet
Matthias Nahrendorf
Research05 Dec 2023
Nature Cardiovascular Research

Volume: 2, P: 1277-1290
Impact of metformin, statin, aspirin and insulin on the prognosis of uHCC patients receiving first line Lenvatinib or Atezolizumab plus Bevacizumab

Margherita Rimini
Margarida Montes
Jose Presa
ResearchOpen Access30 Aug 2024
Scientific Reports

Volume: 14, P: 1-14
Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma

Genomic, transcriptomic, and microenvironmental analyses of samples from patients with glioblastoma treated with nivolumab or pembrolizumab identifies features associated with treatment response that may help in refining patient stratification.

Junfei Zhao
Andrew X. Chen
Raul Rabadan
Research11 Feb 2019
Nature Medicine

Volume: 25, P: 462-469